[go: up one dir, main page]

CO2022007953A2 - Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr - Google Patents

Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr

Info

Publication number
CO2022007953A2
CO2022007953A2 CONC2022/0007953A CO2022007953A CO2022007953A2 CO 2022007953 A2 CO2022007953 A2 CO 2022007953A2 CO 2022007953 A CO2022007953 A CO 2022007953A CO 2022007953 A2 CO2022007953 A2 CO 2022007953A2
Authority
CO
Colombia
Prior art keywords
conditions mediated
heteroarylaminosulfonamides
membered
cftr activity
treat conditions
Prior art date
Application number
CONC2022/0007953A
Other languages
English (en)
Inventor
Zhongli Gao
Gregory Hurlbut
Junkai Liao
Mark Munson
Sylvie Baltzer
Bertrand Vivet
Brian Freed
Hans Peter Nestler
Helen Yeoman
Ingrid Mechin
Martin Smrcina
Nina Ma
Sylvain Lebreton
Ryan Hartung
William Wire
Sukanthini Thurairatnam
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CO2022007953A2 publication Critical patent/CO2022007953A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención está relacionada con compuestos de heteroarilo, sales farmacéuticamente aceptables de estos, y preparaciones farmacéuticas de estos. En la presente también se describen composiciones y el uso de esos compuestos en métodos de tratamiento de enfermedades y afecciones mediadas por la deficiencia de la actividad del CFTR, en particular la fibrosis quística.
CONC2022/0007953A 2019-11-12 2022-06-03 Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr CO2022007953A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962934293P 2019-11-12 2019-11-12
PCT/US2020/060180 WO2021097057A1 (en) 2019-11-12 2020-11-12 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity

Publications (1)

Publication Number Publication Date
CO2022007953A2 true CO2022007953A2 (es) 2022-09-09

Family

ID=73740547

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0007953A CO2022007953A2 (es) 2019-11-12 2022-06-03 Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr

Country Status (17)

Country Link
US (1) US20240002374A1 (es)
EP (1) EP4058439A1 (es)
JP (2) JP7721517B2 (es)
KR (1) KR20220115829A (es)
CN (1) CN115003659A (es)
AU (1) AU2020384279A1 (es)
BR (1) BR112022009185A2 (es)
CA (1) CA3158057A1 (es)
CL (1) CL2022001245A1 (es)
CO (1) CO2022007953A2 (es)
EC (1) ECSP22046050A (es)
IL (1) IL292966A (es)
JO (1) JOP20220105A1 (es)
MX (1) MX2022005809A (es)
PE (1) PE20221461A1 (es)
PH (1) PH12022551139A1 (es)
WO (1) WO2021097057A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3752510T (lt) 2018-02-15 2023-04-11 Vertex Pharmaceuticals Incorporated Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US11584761B2 (en) 2019-08-14 2023-02-21 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
EP4013760A1 (en) 2019-08-14 2022-06-22 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
EP4225737A1 (en) * 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN113480416B (zh) * 2021-07-12 2023-03-21 重庆大学 一种芳基酮的制备方法
KR20240168370A (ko) 2022-03-30 2024-11-29 이시하라 산교 가부시끼가이샤 피리다지논계 화합물 또는 그의 염 및 그들을 함유하는 유해 생물 방제제
CN114835655A (zh) * 2022-04-14 2022-08-02 河南师范大学 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法
WO2024097227A1 (en) 2022-10-31 2024-05-10 Sionna Therapeutics Methods of treating cftr-mediated diseases or disorders
WO2025017207A1 (en) * 2023-07-20 2025-01-23 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibitors of smndc1 and their therapeutic use
WO2025076235A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654125B2 (en) * 1991-03-07 1994-10-27 Hisamitsu Pharmaceutical Co., Inc. Novel diphenylthyazole derivative
CA2206315A1 (en) * 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
EP1441732A2 (en) * 2001-11-08 2004-08-04 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivative and pharmaceutical use thereof
ZA200602755B (en) * 2003-09-06 2007-06-27 Vertex Pharma Modulators of ATP-binding cassette transporters
JP6058645B2 (ja) * 2011-06-10 2017-01-11 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）Ｐｓｌ結合分子およびその使用
WO2016183173A1 (en) * 2015-05-12 2016-11-17 Avista Pharma Solutions Antiparasitic compounds
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
TW201811766A (zh) * 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
WO2024097227A1 (en) * 2022-10-31 2024-05-10 Sionna Therapeutics Methods of treating cftr-mediated diseases or disorders

Also Published As

Publication number Publication date
JP2023500408A (ja) 2023-01-05
ECSP22046050A (es) 2022-08-31
BR112022009185A2 (pt) 2022-07-26
PE20221461A1 (es) 2022-09-21
KR20220115829A (ko) 2022-08-18
JP2025160375A (ja) 2025-10-22
IL292966A (en) 2022-07-01
JP7721517B2 (ja) 2025-08-12
CL2022001245A1 (es) 2023-03-10
WO2021097057A1 (en) 2021-05-20
EP4058439A1 (en) 2022-09-21
AU2020384279A1 (en) 2022-05-26
JOP20220105A1 (ar) 2023-01-30
CA3158057A1 (en) 2021-05-20
MX2022005809A (es) 2022-06-08
US20240002374A1 (en) 2024-01-04
PH12022551139A1 (en) 2023-07-17
CN115003659A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
CO2022007953A2 (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr
CO2022007946A2 (es) Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de cftr deficiente
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
EP4506001A3 (en) SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
MX2019013954A (es) Inhibidores covalentes de kras.
ECSP24025925A (es) Compuestos de indol y métodos de uso
EP4374851A3 (en) Ophthalmic composition for treatment of dry eye disease
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
EP4252755A3 (en) Therapeutic compounds
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
EP4427815A3 (en) Deuterium-enriched pirfenidone and methods of use thereof
MX2021007032A (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos.
PH12017501668A1 (en) Bace1 inhibitors
EA201991817A1 (ru) Интраназальная композиция, включающая бетагистин
DOP2021000028A (es) Formulaciones de dendrímeros
CO2025000163A2 (es) Compuestos, composiciones y métodos de uso de los mismos
WO2018067638A3 (en) High mobility group b1 protein inhibitors
AR108792A1 (es) Composiciones que comprenden timolol
AR108793A1 (es) Composiciones que comprenden timolol y un agente antiinflamatorio
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
EA202090298A1 (ru) Способы лечения муковисцидоза